• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Chromadex Corp CS (NQ: CDXC )

    3.510 +0.220 (+6.69%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 450,811
    Open 3.310
    Bid (Size) 3.520 (1)
    Ask (Size) 3.600 (17)
    Prev. Close 3.290
    Today's Range 3.310 - 3.665
    52wk Range 1.250 - 4.650
    Shares Outstanding 68,196,526
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
    From ChromaDex Corporation
    Via Business Wire

    Performance

    YTD
    +145.45%
    +145.45%
    1 Month
    +10.03%
    +10.03%
    3 Month
    +26.71%
    +26.71%
    6 Month
    +112.73%
    +112.73%
    1 Year
    +134.00%
    +134.00%

    More News

    Read More
    CDXC Stock Earnings: ChromaDex Misses Revenue for Q2 2024
    Via InvestorPlace
    ChromaDex Corporation Reports Second Quarter 2024 Financial Results
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Join Russell 2000® Index
    From ChromaDex Corporation
    Via Business Wire
    Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
    From ChromaDex Corporation
    Via Business Wire
    Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
    From ChromaDex Corporation
    Via Business Wire
    CDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    ChromaDex Corporation Reports First Quarter 2024 Financial Results
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
    From ChromaDex Corporation
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.